LAB
Standard BioTools Inc.
LAB trails on the overall score without a compensating advantage in the available component scores.
UNH
UnitedHealth Group Incorporated
UNH has the edge over LAB overall, supported by stronger fundamentals and lower modeled downside.
LAB Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Unavailable |
LAB's profitability is currently stable, but its revenue and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
LAB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 1.9x | $0.65 | — |
| Cheap | 2.9x | $0.98 | +51% |
| Fair | 3.6x | $1.21 | +86% |
| Expensive | 4.7x | $1.61 | +147% |
Historical ranges are pointers, not guarantees.
LAB has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
LAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect LAB's losses to grow, with revenue growing.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
LAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.34 | +$0.65 |
| Q2 2026 | $0.22 | +$0.51 |
| Q1 2026 | $0.20 | +$0.52 |
| Q4 2025 | -$0.20 | +$0.32 |
| Q3 2025 | -$0.31 | +$0.39 |
| Q2 2025 | -$0.29 | +$0.61 |
| Q1 2025 | -$0.32 | +$0.68 |
| Q4 2024 | -$0.52 | +$0.42 |
LAB has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
LAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.4M | -0.9% |
| Q2 2026 | $20.1M | -7.6% |
| Q1 2026 | $21.1M | -48% |
| Q4 2025 | $23.8M | -49% |
| Q3 2025 | $19.6M | -57% |
| Q2 2025 | $21.8M | -42% |
| Q1 2025 | $40.8M | -10% |
| Q4 2024 | $46.7M | +66% |
LAB's revenue has slid since its 2024 peak: $19M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -102% | +67 points |
| Q2 2026 | -126% | -8.2 points |
| Q1 2026 | -59% | +22 points |
| Q4 2025 | -104% | -33 points |
| Q3 2025 | -168% | -98 points |
| Q2 2025 | -118% | +18 points |
| Q1 2025 | -81% | +51 points |
| Q4 2024 | -70% | +5.6 points |
LAB's operating margin was −102% last quarter, up 66 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over LAB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over LAB on profitability, with a higher operating margin.
LAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.2M | +$16.9M |
| Q2 2026 | -$10.7M | +$11.9M |
| Q1 2026 | -$47.2M | -$11.8M |
| Q4 2025 | -$1.7M | +$15.8M |
| Q3 2025 | -$23.1M | +$7M |
| Q2 2025 | -$22.6M | +$18.4M |
| Q1 2025 | -$35.3M | +$27.9M |
| Q4 2024 | -$17.4M | -$3.3M |
LAB has burned cash in almost every quarter: −$66M over the past year, against −$98M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over LAB on cash generation, producing positive trailing cash flow while its opponent burns cash.
LAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +2.7M shares |
| 1 year | +2.9% | +10.9M shares |
| 3 years | +397% | +314M shares |
| 5 years | +416% | +317M shares |
| Available history | +489% | +327M shares |
LAB has 394M diluted shares, up 2.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $29.4M |
| Q1 2024 | $11.1M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over LAB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
LAB Net Leverage
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
LAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.4 | Neutral |
| Stochastic | 16.7 | Oversold |
LAB's weekly RSI is 39 (neutral) and its Stochastic is 17 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
LAB PE vs Healthcare Sector
| Metric | LAB | Sector median | Relative |
|---|---|---|---|
| PE | 1.9x | 26x | 93% below |
| PE % | 4 | 29 | 25 pts below |
LAB has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
LAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.66 | 1.5% below |
| 20 week MA | $0.74 | 12% below |
| 50 week MA | $0.97 | 33% below |
| 100 week MA | $1.14 | 43% below |
| 200 week MA | $1.66 | 61% below |
LAB is in a downtrend: it's below all five of its weekly moving averages, and 61% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over LAB on trend strength, trading above more of its moving averages.
LAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.36 | $6.48 | +93% |
| 2021 | $6.48 | $3.80 | -41% |
| 2022 | $3.80 | $1.35 | -64% |
| 2023 | $1.35 | $2.21 | +64% |
| 2024 | $2.21 | $1.82 | -18% |
| 2025 | $1.82 | $1.38 | -24% |
| 2026 YTD | $1.38 | $0.65 | -53% |
LAB has finished lower in four of the last six years. It's down 53% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over LAB on returns for 2026, with the stronger performance.